A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study will investigate the safety, efficacy and pharmacokinetics of R3421 in patients
with moderate to severe chronic plaque psoriasis. Patients will be randomized to one of 3
treatment groups to receive once daily oral treatment with a)R3421 20mg, b)R3421 120mg, or
c)placebo. The anticipated time on study treatment is <3 months, and the target sample size
is <100 individuals.